Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial

Research output: Contribution to journalReviewResearchpeer-review


  1. Efficacy of the COVID-19 vaccine in heart transplant recipients: what we know and what we ignore

    Research output: Contribution to journalEditorialResearchpeer-review

  1. Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Left Ventricular Assist Devices at the Crossroad of Innovation in Advanced Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Mandeep R Mehra
  • Daniel L Crandall
  • Finn Gustafsson
  • Ulrich P Jorde
  • Jason N Katz
  • Ivan Netuka
  • Nir Uriel
  • Jean M Connors
  • Poornima Sood
  • Gerald Heatley
  • Francis D Pagani
View graph of relations

AIMS: Over decades, left ventricular assist device (LVAD) technology has transitioned from less durable bulky pumps to smaller continuous-flow pumps which have substantially improved long-term outcomes and quality of life. Contemporary LVAD therapy is beleaguered by haemocompatibility-related adverse events including thrombosis, stroke and bleeding. A fully magnetically levitated pump, the HeartMate 3 (HM3, Abbott, USA) LVAD, has been shown to be superior to the older HeartMate II (HMII, Abbott, USA) pump by improving haemocompatibility. Experience with the HM3 LVAD suggests near elimination of de-novo pump thrombosis, a marked reduction in stroke rates, and only a modest decrease in bleeding complications. Since the advent of continuous-flow LVAD therapy, patients have been prescribed a combination of aspirin and anticoagulation therapy on the presumption that platelet activation and perturbations to the haemostatic axis determine their necessity. Observational studies in patients implanted with the HM3 LVAD who suffer bleeding have suggested a signal of reduced subsequent bleeding events with withdrawal of aspirin. The notion of whether antiplatelet therapy can be avoided in an effort to reduce bleeding complications has now been advanced.

METHODS: To evaluate this hypothesis and its clinical benefits, the Antiplatelet Removal and Hemocompatibility Events with the HeartMate 3 Pump (ARIES HM3) has been introduced as the first-ever international prospective, randomized, double-blind and placebo-controlled, non-inferiority trial in a patient population implanted with a LVAD.

CONCLUSION: This paper reviews the biological and clinical role of aspirin (100 mg) with LVADs and discusses the rationale and design of the ARIES HM3 trial.

Original languageEnglish
JournalEuropean Journal of Heart Failure
Issue number7
Pages (from-to)1226-1237
Publication statusPublished - 2021

Bibliographical note

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

    Research areas

  • Aspirin, Heart Failure/therapy, Heart-Assist Devices, Humans, Prospective Studies, Quality of Life, Randomized Controlled Trials as Topic, Mechanical Circulatory Support, Assist devices, Hemocompatibility, Bleeding, LVAD, Outcomes, Advanced heart failure

ID: 68254923